Insight journal - Company

Nektar Therapeutics: Partnering activity 2009-2014

Posted on 13 October 2014

Tags: , , ,

Nektar Therapeutics is a leading biopharma company headquartered in San Francisco. The company is listed in the top 50 big biotech list by Current Partnering. The company is a world leader in polymer chemistry which involves the design of drugs with optimized drug pharmacology.

Nektar Therapeutics announced only about 3 partnering / licensing deals since 2009. The company has had several strategic partnerships in the past for compounds, reagents and technology with companies like AstraZeneca, Bayer, Pfizer, Roche, etc

The company has not entered into any partnerships recently. The company is developing a diverse and deep pipeline of products covering carious therapeutic disciplines some of which are still in the early stages of development. This could be a potential lure for partners to enter into a strategic collaboration with the company.

The following figure shows the level of Nektar Therapeutics partnering deal announcements since 2009.

Figure 1: Nektar Therapeutics partnering deals 2009-2014

1

 

 

 

 

 

 

 

Source: Current Agreements, 2014

The following table provides an overview of the partnering deals announced by Nektar Therapeutics based on specific therapy area disclosed.

Figure 2: Nektar Therapeutics partnering deals by therapy area 2009-2014

 

2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2014

Further analysis of these deals shows that Nektar Therapeutics has a preference for licensing and supply deals.

The following table provides an overview of the partnering deals announced by Nektar Therapeutics based on deal type disclosed.

Figure 3: Nektar Therapeutics partnering deals by deal type 2009-2014

 

3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2014

Nektar Therapeutics is constantly searching for partners to co develop and jointly discover next generation of successful drugs to meet critical unmet needs.

The following table provides an overview of the partnering deals announced by Nektar Therapeutics based on stage of development at signature.

Figure 4: Nektar Therapeutics partnering by stage of development 2009-2014

 

4

 

 

 

 

 

 

 

 

Source: Current Agreements, 2014

Nektar Therapeutics has entered into high value licensing deals- Eg: In Sep 2009, AstraZeneca and Nektar Therapeutics entered into a licensing agreement for compounds NKTR-118 and NKTR-119 which were compounds developed against pain and constipation. The deal was valued at $735 million that included upfront and milestone payments and was also promised double digit royalty rates on net sale of the compounds.

As an emerging big biotech company, Nektar Therapeutics is working towards being a market leader for novel therapeutics with advanced polymer conjugate technologies.

Nektar Therapeutics partnering at Current Agreements

View all partnering deals for Nektar Therapeutics: 2014 | 2013 | 2012 | 2011 | 2010 | 2009

Full details on each deal can be found at CurrentAgreements (subscription required)

Or purchase report: Partnering Agreements with Nektar Therapeutics 2009-2014

More

Summary profile for Nektar Therapeutics

Partnering interests for Nektar Therapeutics

No M&A activity for Nektar Therapeutics

 

Available reports from Current Partnering

Report: Top 50 Big Pharma Partnering and M&A Deals and Alliances

Report: Top 50 Big Biotech Partnering and M&A Deals and Alliances

 

Available resources for deal coverage for Nektar Therapeutics

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Nektar Therapeutics company profile, recent partnering, M&A and financing news and articles

 

Related

View: CP Insight’s Partnering Scorecard – view top life science partnering deals by value

View:  CP Insight’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

 

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

 

Print Friendly, PDF & Email

Leave a Reply